Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia.

@article{Deardorff2019BehavioralAP,
  title={Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia.},
  author={William James Deardorff and George T. Grossberg},
  journal={Handbook of clinical neurology},
  year={2019},
  volume={165},
  pages={
          5-32
        }
}
Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent and represent a significant burden for patients and their caregivers. Early recognition and management of these symptoms is crucial as they are associated with increased risk of institutionalization, impairments in daily functioning, reduced quality of life, and more rapid progression to severe dementia. This chapter will discuss the pathophysiology, proposed diagnostic criteria, clinical features, and management of… 
Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System
TLDR
Effective therapies are needed to address agitation in dementia, with the potential to alleviate patient impact, HCRU, and healthcare costs.
Behavioral and Psychological Symptoms of Dementia (BPSD): Clinical Characterization and Genetic Correlates in an Italian Alzheimer’s Disease Cohort
TLDR
The combined use of both BPSD single symptoms/endophenotypes and the “genexgene” interactions are strongly suggested as valid strategies for expanding the knowledge about the B PSD aetiopathogenetic mechanisms.
Relieving Caregiver Burden Through Evidence-Based Treatment for Dementia-Related Psychosis.
TLDR
Clinicians should follow guidelines recommendations, such as using medication only if the patient or others are in severe distress or danger and starting with low doses and long-term treatment is not recommended.
Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview
TLDR
A comprehensive overview of the literature on AD, the current and potential therapy of both cognitive symptoms as well as BPSD, with a special focus on gut microbiota and epigenetic modifications as new emerging drug targets is provided.
Depression as a Risk Factor for Dementia and Alzheimer’s Disease
TLDR
Depression and diabetes mellitus increase the risk of dementia, whereas treated dyslipidemia has been shown to reduce this risk.
The Influence of Telemedicine Care on the Management of Behavioral and Psychological Symptoms in Dementia (BPSD) Risk Factors Induced or Exacerbated During the COVID-19 Pandemic
TLDR
Telemedicine can reduce the risk for the development of negative outcomes in mental health precipitated by the reduction of social contact and less access to health services, improving dementia symptom management, mainly BPSD.
Neuropsychiatric Symptoms Among Hispanics: Results of the Maracaibo Aging Study.
TLDR
Neuropsychiatric symptoms are associated with severe cognitive impairment and dementia in Hispanics, and the addition of NPI items to the global cognitive assessment might help early detection of dementia in primary care settings.
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
  • R. Cacabelos
  • Medicine
    International journal of molecular sciences
  • 2020
TLDR
The incorporation of pharmacogenomic strategies for a personalized treatment in dementia is an effective option to optimize limited therapeutic resources and to reduce unwanted side-effects.
Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
TLDR
Biochemical, hematological, and metabolic differences may contribute to changes in drug efficacy and safety and APOE-4 carriers and CYP-related PMs and UMs deserve special attention for their vulnerability and poor response to current treatments.
Physician-Assisted Suicide in Dementia: Paradoxes, Pitfalls and the Need for Prudence
TLDR
It is suggested that the practice of PAS in dementia is not one that can be widely or safely endorsed, on both cultural and ethical grounds, and the medical field should work in collaboration with governmental, social welfare and patient advocacy services to ensure optimal physical, emotional and financial support to this group of patients and their caregivers.
...
1
2
3
...

References

SHOWING 1-10 OF 225 REFERENCES
The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.
TLDR
The APA's most recent practice guideline on antipsychotic treatment in patients with dementia appears to have done just that, with a thorough, balanced, accurate, and current review of available treatments based on medical and scientific literature.
Management of Neuropsychiatric Symptoms of Dementia in Clinical Settings: Recommendations from a Multidisciplinary Expert Panel
TLDR
An approach is constructed describing the sequential and iterative steps of managing NPS in real‐world clinical settings that can be used as a basis for integrating nonpharmacological and pharmacological approaches and could be implemented in research and clinical care.
Differences of Behavioral and Psychological Symptoms of Dementia in Disease Severity in Four Major Dementias
TLDR
The aims of this study were to clarify the differences of trajectories of 12 kinds of BPSDs by disease severity in four major dementias and to develop charts showing the frequency, severity, and associated caregiver distress of B PSDs using the data of a Japan multicenter study (J-BIRD).
Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions
TLDR
It is suggested that music therapy is optimal for the management of agitation in institutionalized patients with moderately severe and severe AD, particularly when the intervention includes individualized and interactive music.
Treating Depression in Older Adults with Dementia
  • E. Lenze
  • Medicine
    Journal of the American Geriatrics Society
  • 2011
TLDR
The main finding here is that the question “How do I treat depressive symptoms in my demented patients” remains incompletely answered, and the marginal findings in this meta-analysis are due to modest efficacy of antidepressants for older adults in general.
A review of neuroimaging findings of apathy in Alzheimer's disease
TLDR
Neuroimaging findings lend support to the notion that frontal-subcortical networks are involved in the occurrence of apathy in AD and reveal disease patterns, helping to distinguish clinically distinct cognitive syndromes, and allowing predictions.
Nonpharmacologic Interventions for Psychotic Symptoms in Dementia
TLDR
The term psychosisshould be abandoned for most dementia patients, and assessments of etiology should be developed, and future research should clarify what proportion of symptoms currently identified as psychotic are attributable to related etiologies.
Longitudinal course of behavioural and psychological symptoms of dementia: systematic review
TLDR
There were clinically relevant differences in the longitudinal courses of different BPSD, and apathy was the only symptom with high baseline prevalence, persistence and incidence during the course of dementia.
Behavioral Problems and Dementia.
  • L. Volicer
  • Medicine
    Clinics in geriatric medicine
  • 2018
TLDR
Pharmacologic management should concentrate on treatment of main dementia consequences, especially depression, instead of treating secondary symptoms, for example, insomnia, and use of antipsychotics should be minimized but antipsychotic may be necessary for augmentation of antidepressants.
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
TLDR
This post hoc analysis provides important evidence from placebo-controlled trials that memantine may be a safe and effective treatment in Alzheimer's disease patients with agitation/aggression or psychosis, who are otherwise prone to rapid progression.
...
1
2
3
4
5
...